Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | PTGFR | P43088 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079492 | 0.86 | XDH (0.41) | XDHMRGPRX4MAOB | |
| SCHEMBL6079324 | 0.81 | CTSV (0.40) | PTGER1PTGFR | |
| SCHEMBL6592622 | 0.80 | XDH (0.51) | XDHPTGER1MCL1 | |
| SCHEMBL6079907 | 0.77 | PTGER1 (0.43) | PTGER1THRATHRB | |
| SCHEMBL6081248 | 0.77 | THRA (0.41) | PTGER1MCL1THRATHRB | |
| SCHEMBL6594157 | 0.77 | XDH (0.40) | XDHMRGPRX4MAOBTHRATHRB | |
| SCHEMBL6080219 | 0.77 | KMT2A (0.39) | MRGPRX4 | |
| SCHEMBL6080139 | 0.77 | DHODH (0.36) | PTGFR | |
| SCHEMBL6079768 | 0.75 | ALDH1A1 (0.38) | PTGER1MCL1 | |
| SCHEMBL6079938 | 0.75 | XDH (0.43) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | XDH 128/4885PTGER1 1819/4885MRGPRX4 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.